Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL478919 | 1.00 | YAP1 (0.51) | YAP1KDM4EPKMP2RX7MAPT | |
| SCHEMBL478951 | 0.88 | KYNU (0.44) | YAP1P2RX7MAPTMEN1KMT2A | |
| SCHEMBL478953 | 0.88 | KYNU (0.44) | YAP1P2RX7MAPTMEN1KMT2A | |
| SCHEMBL2999882 | 0.88 | YAP1 (0.62) | YAP1KDM4EPKMP2RX7MAPT | |
| SCHEMBL2999886 | 0.88 | YAP1 (0.62) | YAP1KDM4EPKMP2RX7MAPT | |
| SCHEMBL8147986 | 0.88 | YAP1 (0.62) | YAP1KDM4EPKMP2RX7MAPT | |
| SCHEMBL27998434 | 0.87 | BCHE (0.44) | CTSKBCHEACHE | |
| SCHEMBL478461 | 0.87 | ACKR3 (0.46) | YAP1P2RX7CTSKBCHE | |
| SCHEMBL478463 | 0.87 | ACKR3 (0.46) | YAP1P2RX7CTSKBCHE | |
| SCHEMBL3008280 | 0.86 | YAP1 (0.60) | YAP1KDM4EPKMP2RX7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2265601-B1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | F11, F12, TFPI2 | YAP1 4075/4885KDM4E 1441/4885PKM 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.